Ann: Appendix 4C - quarterly, page-70

Hi 1m, that “even if we are 1 qt or 2 ...” comment is something that I HOPE is definitely not on the cards, the consequences of that happening could see a languishing of the sp and some loss of credibility.

That there is funds to fall back on (loan facility) it still will cast a cloud over the immediate prospects of this company.

In regards to FDA approval that will be anybodies guess to as the impact on share appreciation.

Imo, I would say little impact until significant revenue or major partnership/ interest with major entity for distribution rights, upfront funds blue sky scenario.

History has shown, very graphically, what happened with FDA on the Cardiocel story, significant hype with no/ little substance in the aftermath.

Sincerely hope that the acquisition of the “higher levels of talent ...’ prove their mettle and not like lex pointed out possibly “run their course”!

Strategic direction is great, hope that the execution of it is also on the lines of great!